Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new player in retinal care just made a big move. Imvionix, a company founded in 2025, has acquired the commercial rights to Beovu (brolucizumab-dbll) from Novartis for the U.S. and Canadian markets. The FDA-approved VEGF inhibitor treats wet age-related macular degeneration and diabetic macular edema, and Imvionix is betting its retina-focused network will help the drug reach more patients.
A new player in retinal care just made a big move. Imvionix, a company founded in 2025 with a focus on the retina space, has acquired the commercial rights to Beovu (brolucizumab-dbll) from Novartis in the United States and Canada. Financial terms of the deal were not disclosed.
Beovu is an intravitreally injected VEGF inhibitor that is FDA approved for two serious retinal conditions: wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Imvionix CEO Rick Eiswirth said the acquisition reflects exactly the kind of opportunity the company was built to pursue, citing its strong connections in the retina community as a key advantage in expanding the drug's reach.
Quick Facts:
Why it matters: This deal signals growing commercial interest in retinal therapeutics and could mean broader patient access to Beovu under a company laser-focused on the retina space.